Compare SHAK & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHAK | TVTX |
|---|---|---|
| Founded | 2004 | 2008 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.3B |
| IPO Year | 2014 | 2013 |
| Metric | SHAK | TVTX |
|---|---|---|
| Price | $93.96 | $27.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 14 |
| Target Price | ★ $115.05 | $36.85 |
| AVG Volume (30 Days) | 1.2M | ★ 1.4M |
| Earning Date | 04-06-2026 | 04-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.81 | N/A |
| Revenue | ★ $1,252,608,000.00 | N/A |
| Revenue This Year | $17.83 | $121.25 |
| Revenue Next Year | $13.69 | $36.79 |
| P/E Ratio | $92.17 | ★ N/A |
| Revenue Growth | ★ 15.18 | N/A |
| 52 Week Low | $72.93 | $12.91 |
| 52 Week High | $142.23 | $42.13 |
| Indicator | SHAK | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.54 | 38.11 |
| Support Level | $86.91 | $27.01 |
| Resistance Level | $99.29 | $31.44 |
| Average True Range (ATR) | 4.43 | 1.87 |
| MACD | -0.40 | -0.12 |
| Stochastic Oscillator | 59.42 | 15.02 |
Shake Shack Inc is a roadside burger stand. It serves a classic American menu of premium burgers, hot dogs, crispy chicken, frozen custard, crinkle-cut fries, shakes, beer, wine and more. The company's burgers are made with a whole-muscle blend of all-natural, hormone and antibiotic-free Angus beef, ground fresh daily, cooked to order, and served on a non-genetically modified organism (GMO) potato bun. Its menu focuses on food and beverages, crafted from a range of classic American foods. The company serves draft Root Beer, seasonal freshly-squeezed lemonade, organic fresh brewed iced tea, cold brew coffee, organic apple juice, and Shack20 bottled water.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.